Wayfair to Expand its World-Class Engineering Team Across North America

Wayfair to Expand its World-Class Engineering Team Across North America

Leader in Home to Open New Offices in San Francisco Bay Area, Austin, Texas and Toronto, Canada

BOSTON–(BUSINESS WIRE)–Wayfair Inc. (NYSE:W), one of the world’s largest online destinations for the home, today announced it will open three new Engineering sites in the San Francisco Bay Area of California, Austin, Texas and the city of Toronto in Ontario, Canada. The company plans to hire approximately 1,000 technologists to its world-class Engineering organization globally over the next year. Wayfair is expanding its Engineering footprint to locations outside of its technology hubs in Boston and Berlin for the first time to further advance the innovative technologies that make Wayfair the best place to shop for home.

“As Wayfair further solidifies its position as the leader in home, we are excited to open a new chapter as an Engineering organization with three new office locations that will help accelerate our ambitious tech agenda,” said Jim Miller, Chief Technology Officer, Wayfair. “We’re thrilled to expand our global talent footprint to Austin, Toronto and the San Francisco Bay Area as we continue to evolve our team to support the incredible growth of the business.”

Wayfair will initially hire for up to 200 positions at each new Wayfair Engineering site over the next year. Positions include software engineers, infrastructure engineers, product managers, experience designers, analysts, and data scientists. The roles will help drive a wide range of solutions, from cutting-edge machine learning and data science techniques that help customers find just the right product among more than 22 million items, to next-generation merchandising that fuels beautiful, inspiring product imagery, to platforms that enable suppliers to reach consumers more effectively and grow their businesses.

The company also plans to continue hiring engineering and data science talent across its global headquarters in Boston and its European headquarters in Berlin. Wayfair currently employs more than 3,000 engineers and data scientists.

“We’re looking forward to opening three new Engineering sites within the next year,” continued Miller. “These new locations will be an extension of our headquarters in Boston and Berlin and will allow us to continue to build and foster a global community of sophisticated technologists who are powering the best possible shopping experience for home.”

Candidates interested in technical positions across all of Wayfair’s hubs in Boston, Berlin, Austin, Toronto and the San Francisco Bay Area, can visit wayfair.com/careers to apply.

About Wayfair

Wayfair believes everyone should live in a home they love. Through technology and innovation, Wayfair makes it possible for shoppers to quickly and easily find exactly what they want from a selection of more than 22 million items across home furnishings, décor, home improvement, housewares and more. Committed to delighting its customers every step of the way, Wayfair is reinventing the way people shop for their homes – from product discovery to final delivery.

The Wayfair family of sites includes:

  • Wayfair – Everything home for every budget.
  • Joss & Main – Stylish designs to discover daily.
  • AllModern – The best of modern, priced for real life.
  • Birch Lane – Classic home. Comfortable cost.
  • Perigold – The widest-ever selection of luxury home furnishings.

Wayfair generated $14.1 billion in net revenue for full year 2020. Headquartered in Boston, Massachusetts with operations throughout North America and Europe, Wayfair employs more than 16,000 people.

Media Relations Contact:

John Costello

[email protected]

Investor Relations Contact:

Jane Gelfand

[email protected]

KEYWORDS: United States North America Canada Massachusetts California Texas

INDUSTRY KEYWORDS: Online Retail Retail Technology Home Goods Software Internet

MEDIA:

Logo
Logo

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis

MIAMI–(BUSINESS WIRE)–
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of knee osteoarthritis.

This approved trial design, which will begin in the second quarter of this year, will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of Zofin™ for patients suffering with knee osteoarthritis.

Zofin™ is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues.

According to the Centers for Disease Control and Prevention, osteoarthritis (OA) is the most common form of arthritis and affects over 32 million adults in the US. It occurs most frequently in the hands, hips, and knees, where the cartilage within the joints begin to break down and the underlying bones begin to change. It is a chronic disease, and these changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling, and in some cases, causes reduced function and disability; some people are no longer able to do daily tasks or work.

“Osteoarthritis is a very common, degenerative disease with no cure or long-term treatment strategy,” said Dr. Mari Mitrani, Chief Science Officer of Organicell. “We are excited to initiate this FDA approved clinical trial and to further explore the potential of Zofin™ in battling this disease.”

About Zofin™:

Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection.

ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

FORWARD-LOOKING STATEMENTS

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Media:

Jeffrey Freedman

RooneyPartners

646-432-0191

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Stem Cells Biotechnology Alternative Medicine FDA Health Other Science Research Infectious Diseases Hospitals Science Clinical Trials

MEDIA:

Logo
Logo

Gibraltar Industries to Announce First Quarter 2021 Financial Results on May 5

Gibraltar Industries to Announce First Quarter 2021 Financial Results on May 5

BUFFALO, N.Y.–(BUSINESS WIRE)–Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the renewable energy, conservation, residential and infrastructure markets, announced today that it expects to release its first quarter 2021 financial results at approximately 7:30 a.m. ET on Wednesday, May 5, 2021. It also expects to discuss the results on a conference call that will be webcast live that same day starting at 9:00 a.m. ET. Hosting the call will be Chief Executive Officer William Bosway and Chief Financial Officer Timothy Murphy.

Those who wish to listen to the conference call should visit the Investors section of the Company’s website at www.gibraltar1.com. The call also may be accessed by dialing (877) 407-3088 or (201) 389-0927. For interested individuals unable to join the live conference call, a webcast replay will be available on the Company’s website for one year.

About Gibraltar

Gibraltar Industries is a leading manufacturer and provider of products and services for the renewable energy, conservation, residential, and infrastructure markets. With a three-pillar strategy focused on business systems, portfolio management, and organization and talent development, Gibraltar’s mission is to create compounding and sustainable value with strong leadership positions in higher growth, profitable end markets. Gibraltar serves customers primarily throughout North America. Comprehensive information about Gibraltar can be found on its website at www.gibraltar1.com.

Timothy Murphy

Chief Financial Officer

(716) 826-6500 ext. 3277

[email protected]

LHA Investor Relations

Carolyn Capaccio/Jody Burfening

(212) 838-3777

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Utilities Construction & Property Environment Other Manufacturing Alternative Energy Energy Manufacturing Residential Building & Real Estate

MEDIA:

Logo
Logo

Star Peak Energy Transition Corp. Reminds Stockholders to Vote in Favor of Business Combination with Stem, Inc.

Star Peak Energy Transition Corp. Reminds Stockholders to Vote in Favor of Business Combination with Stem, Inc.

EVANSTON, Ill.–(BUSINESS WIRE)–
Star Peak Energy Transition Corp. (“Star Peak” or “the Company”) (NYSE: STPK), a publicly traded special purpose acquisition company, reminds its holders of common stock to vote in favor of the approval of the Company’s proposed business combination with Stem, Inc. (“Stem”), a global leader in artificial intelligence (AI)-driven clean energy storage systems, and the related proposals to be voted upon at the Company’s virtual Special Meeting on April 27, 2021.

The Special Meeting to approve the pending business combination is scheduled for Tuesday, April 27, 2021, at 11:00 a.m. ET. It will be completely virtual and conducted via live webcast via the following link: https://www.cstproxy.com/starpeakcorp/2021. Holders of Star Peak’s shares of common stock at the close of business on the record date of March 4, 2021 are entitled to notice of the virtual Special Meeting and should vote before 11:59 p.m. ET on April 26, 2021.

If the proposals at the Special Meeting are approved, the parties anticipate that the business combination will close shortly thereafter, subject to the satisfaction or waiver (as applicable) of all other closing conditions.

It remains important that all holders who owned Star Peak common stock as of March 4, 2021 – even if they have since sold – vote by the April 26, 2021 deadline to ensure the deal proceeds in a timely manner.

There are three ways to vote: online, via telephone or by mail. More information on how to vote can be found at https://stpk.starpeakcorp.com/vote. Holders of Star Peak common stock who need assistance voting or have questions regarding the Special Meeting may contact Star Peak’s proxy solicitor, Morrow Sodali, toll-free at (877) 787-9239 or email Morrow Sodali at [email protected].

About Stem

Stem provides solutions that address the challenges of today’s dynamic energy market. By combining advanced energy storage solutions with Athena™, a world-class artificial intelligence (AI)-powered analytics platform, Stem enables customers and partners to optimize energy use by automatically switching between battery power, onsite generation and grid power. Stem’s solutions help enterprise customers benefit from a clean, adaptive energy infrastructure and achieve a wide variety of goals, including expense reduction, resilience, sustainability, environmental and corporate responsibility and innovation. Stem also offers full support for solar partners interested in adding storage to standalone, community or commercial solar projects – both behind and in front of the meter.

Headquartered in Millbrae, Calif., Stem is directly funded by a consortium of leading investors including Activate Capital, Angeleno Group, BNP Paribas, Constellation Technology Ventures, Copec, Iberdrola (Inversiones Financieras Perseo), GE Ventures, Magnesium Capital, Mithril Capital Management, Mitsui & Co. LTD., Ontario Teachers’ Pension Plan, RWE Supply & Trading, Temasek and Total Energy Ventures. For more information, visit www.stem.com.

About Star Peak Energy Transition Corp.

Star Peak is a blank check company incorporated in Delaware for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Star Peak is led by a management team with extensive experience investing in the energy, energy infrastructure and renewables sectors, including Chairman, Michael Morgan and Chief Executive Officer, Eric Scheyer. Michael Morgan is Chairman and Chief Executive Officer at Triangle Peak Partners LP and currently serves as a director of Sunnova Energy International (NYSE: NOVA) and lead director of Kinder Morgan, Inc. (NYSE: KMI), one of the largest energy infrastructure companies in North America, a company he joined at its founding in 1997. Eric Scheyer is a Partner at Magnetar and has served as the Head of the Magnetar Energy and Infrastructure Group since its inception in 2005. For more information, visit https://stpk.starpeakcorp.com/.

Additional Information

This communication is being made in respect of a proposed merger transaction (the “proposed transactions”) involving Star Peak and Stem. The proposed transactions will be submitted to stockholders of Star Peak for their consideration and approval at a special meeting of stockholders. In connection with the proposed transactions, Star Peak has filed a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”), which includes a definitive proxy statement / prospectus / written consent solicitation that has been distributed to Star Peak stockholders in connection with Star Peak’s solicitation for proxies for the vote by Star Peak’s stockholders in connection with the proposed transactions and other matters as described in such Registration Statement, as well as the prospectus relating to the offer of the securities. Star Peak has mailed a definitive proxy statement / prospectus / written consent solicitation and other relevant documents to its stockholders as of the record date established for voting on the proposed transactions. Investors and security holders of Star Peak are advised to read the definitive proxy statement / prospectus / written consent solicitation in connection with Star Peak’s solicitation of proxies for its special meeting of stockholders to be held to approve the proposed transaction because the proxy statement / prospectus / written consent solicitation contains important information about the proposed transaction and the parties to the proposed transaction. Stockholders may also obtain copies of the definitive proxy statement / prospectus / written consent solicitation, without charge at the SEC’s website at www.sec.gov or by directing a request to: Star Peak Energy Transition Corp., 1603 Orrington Ave., 13 Floor Evanston, IL 60201.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Participants in the Solicitation

Star Peak and Stem and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Star Peak’s stockholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Star Peak s stockholders in connection with the proposed business combination is set forth in Star Peak’s registration statement / proxy statement that has been filed with the SEC. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Star Peak’s directors and officers in Star Peak’s filings with the SEC, and such information is also in the Registration Statement that has been filed with the SEC by Star Peak, which includes the definitive proxy statement / prospectus / written consent solicitation of Star Peak for the proposed transaction.

Forward-Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events of Star Peak or Stem’s future financial or operating performance. For example, projections of future revenue and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “or“ or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Star Peak and its management, and Stem and its management, as the case may be, are inherently uncertain factors that may cause actual results to differ materially from current expectations include, but are not limited to: 1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive merger agreement with respect to the business combination; 2) the outcome of any legal proceedings that may be instituted against Star Peak, the combined company or others following the announcement of the business combination and any definitive agreements with respect thereto; 3) the inability to complete the business combination due to the failure to obtain approval of the stockholders of Star Peak, to obtain financing to complete the business combination or to satisfy other conditions to closing; 4) changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the business combination; 5) the ability to meet the New York Stock Exchange’s listing standards following the consummation of the business combination; 6) the risk that the business combination disrupts current plans and operations of Stem as a result of the announcement and consummation of the business combination; 7) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; 8) costs related to the business combination; 9) changes in applicable laws or regulations; 10) the possibility that Stem or the combined company may be adversely affected by other economic, business and/or competitive factors; 11) Stem’s estimates of its financial performance; 12) the impact of the novel coronavirus disease pandemic and its effect on business and financial conditions; and 13) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Star Peak’s Annual Report on Form 10-K for the year ended December 31, 2020. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Star Peak nor Stem undertakes any duty to update these forward-looking statements, except as otherwise required by law.

Investor Contact – Stem

Ted Durbin, Stem, Inc.

Marc Silverberg, ICR, Inc.

[email protected]

Media Contact – Stem

Cory Ziskind, ICR, Inc.

[email protected]

Star Peak

Tricia Quinn

Courtney Kozel

[email protected]

847 905 4400

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Alternative Energy Energy Environment Other Energy Utilities

MEDIA:

Radius Global Infrastructure Announces First Quarter Earnings Release Date

Radius Global Infrastructure Announces First Quarter Earnings Release Date

NEW YORK–(BUSINESS WIRE)–
Radius Global Infrastructure, Inc. (NASDAQ: RADI) (the “Company”), one of the largest global aggregators of real property interests underlying wireless communications cell sites and other communications infrastructure, today announced that it will release its first quarter financial results on Wednesday, May 12, 2021. Management will host a webcast and conference call on Wednesday, May 12, 2021 at 8:30 A.M. Eastern Time to review financial results, discuss recent events and conduct a question-and-answer session. A copy of the earnings release and presentation slides will be posted to the “Quarterly Results” section of the Company’s website, https://www.radiusglobal.com/filings/quarterly-results.

Webcast and Conference Call:

The live webcast and presentation slides will be available through the “News & Events” section of the Company’s website, https://www.radiusglobal.com/news-events/events-presentations. Participants are advised to go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.

For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-877-407-0789 or 1-201-689-8562, respectively. Upon dialing in, please request to join the Radius Global Infrastructure 2021 First Quarter Earnings Conference Call.

A replay of the webcast and access to the presentation slides will be available on the Company’s website until Wednesday, May 26, 2021, at https://www.radiusglobal.com/news-events/events-presentations.

About the Company:

Radius Global Infrastructure, Inc., through its subsidiary AP Wireless (“APW”), is a multinational owner of a growing, diversified portfolio of triple-net ground, rooftop and other critical communications properties leased to wireless carriers and tower companies underlying their mission critical cell site antenna infrastructure. APW’s proven lease origination engine drives highly attractive yields on capital invested. The Company is also expanding into other digital infrastructure segments and has a broad pipeline of proprietary and non-proprietary acquisitions, investments and build-to-suit opportunities.

For further information see https://www.radiusglobal.com.

Investor Relations:

ICR Inc.

Evelyn Infurna/Nikki Sacks

Email: [email protected]

Phone: (484) 278-2667

Media:

Sard Verbinnen & Co Jim Barron/Jared Levy

Email: [email protected]

(212) 687-8080

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Communications Mobile/Wireless Technology Telecommunications Other Communications

MEDIA:

Quad to Host Call to Discuss First Quarter 2021 Results

Quad to Host Call to Discuss First Quarter 2021 Results

SUSSEX, Wis.–(BUSINESS WIRE)–
Quad (NYSE: QUAD) will hold a conference call at 10 a.m. ET on Wednesday, May 5, to discuss first quarter 2021 results. The call will be hosted by Joel Quadracci, Quad Chairman, President & CEO, and Dave Honan, Quad Executive Vice President & CFO.

The full earnings release and slide presentation will be concurrently available on the Investors section of Quad’s website at www.quad.com/investors. As part of the conference call, Quad will conduct a question and answer session. Investors are invited to email their questions in advance to [email protected].

Participants may pre-register for the webcast by navigating to https://dpregister.com/sreg/10155015/e6ee4a26aa. Participants will be given a unique PIN to gain immediate access to the call on May 5, bypassing the live operator. Participants may pre-register at any time, including up to and after the call start time.

Alternatively, participants without internet access may dial in on the day of the call as follows:

• U.S. Toll-Free: 1-877-328-5508

• International Toll: 1-412-317-5424

An audio replay of the call will be posted on the Investors section of Quad’s website shortly after the conference call ends. In addition, telephone playback will also be available until June 5, 2021, accessible as follows:

• U.S. Toll-Free: 1-877-344-7529

• International Toll: 1-412-317-0088

• Replay Access Code: 10155015

About Quad

Quad (NYSE: QUAD) is a worldwide marketing solutions partner that leverages its 50-year heritage of platform excellence, innovation and strong culture and social purpose to create a better way for its clients, employees and communities. The Company’s integrated marketing platform helps brands and marketers reduce complexity, increase efficiency and enhance marketing spend effectiveness. Quad provides its clients with unmatched scale for client on-site services and expanded subject expertise in marketing strategy, creative solutions, media deployment (which includes a strong foundation in print) and marketing management services. With a client-centric approach that drives the Company to continuously evolve its offering, combined with leading-edge technology and single-source simplicity, the Company has the resources and knowledge to help a wide variety of clients in multiple vertical industries, including retail, publishing, consumer packaged goods, financial services, insurance, healthcare and direct-to-consumer. Quad has multiple locations throughout North America, South America and Europe, and strategic partnerships in Asia and other parts of the world. For additional information visit www.QUAD.com.

Investor Relations Contact

Katie Krebsbach

Investor Relations Lead, Quad

414-566-4247 / [email protected]

Media Contact

Claire Ho

Director of Corporate Communications, Quad

414-566-2955 / [email protected]

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Other Manufacturing Packaging Publishing Other Retail Marketing Communications Manufacturing Catalog Retail

MEDIA:

Logo
Logo

Innoviz Announces Filing of Annual Report on Form 20-F

PR Newswire

TEL AVIV, Israel, April 21, 2021 /PRNewswire/ — Innoviz Technologies Ltd. (Nasdaq: INVZ), a leading provider of high-performance solid-state LiDAR sensors and perception software, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission.

The Annual Report on Form 20-F can be accessed on the Company’s investor relations website at https://ir.innoviz.tech/ and on the SEC’s website at www.sec.gov. The Company’s security holders may request a hard copy of the Annual Report free of charge by visiting the “Contact Us” page of the Company’s website at https://innoviz.tech/contact-us.

About Innoviz Technologies
Innoviz is a leading provider of technology that will put autonomous vehicles on roads, ultimately changing the world and making life better. Innoviz is the only company with LiDAR technology that can “see” better than a human driver, while also meeting the automotive industry’s strict requirements for performance, safety and price. Selected by BMW for its fully electric autonomous car program, Innoviz’s technology will be the first to be deployed in consumer vehicles. Innoviz is backed by top-tier strategic partners and investors, including SoftBank Ventures Asia, Samsung, Magna International, Aptiv, Magma Venture Partners, and others. For more information, visit www.innoviz.tech

Media Contact:


[email protected]

Investor Contact:

Maya Lustig

Innoviz Technologies    
+972 54 6778100 
[email protected] 

Gateway Investor Relations

Cody Slach or Matt Glover
(949) 574-3860
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/innoviz-announces-filing-of-annual-report-on-form-20-f-301273745.html

SOURCE Innoviz Technologies

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma

PR Newswire

NEW YORK, April 21, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021  at 11:00 Eastern. 

 

Oramed Pharmacetuicals Logo

 

Mr. Kidron, along with Premas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu, will discuss Oramed Pharmaceuticals’ oral insulin drug, currently in Phase 3 clinical trials, and the oral COVID-19 vaccine candidate of Oravax Medical Inc., which is 63% owned by Oramed Pharmaceuticals. Pre-clinical trials have shown that Oravax’s oral vaccine candidate produces antibodies after a single dose and may potentially be a better candidate for protection against COVID-19 variants due to triple antigen targeting. Clinical trials are expected to begin this quarter.

Investors and the media may register for the live webinar here: https://us02web.zoom.us/webinar/register/WN_Hbu2sP3sSP2M-YI23AXJpg

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential advantages of Oravax’s vaccine candidate and the expected timing to begin clinical trials, the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact

Estee Yaari

+1-844-9-ORAMED Ext: 2
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/oramed-pharmaceuticals-and-oravax-medical-to-be-featured-in-alliance-global-partners-grand-rounds-a-webinar-in-biotech-and-specialty-pharma-301273620.html

SOURCE Oramed Pharmaceuticals Inc.

Anexinet Honored Within the 2021 CRN® Tech Elite 250 List

Company Rises To The Top For Deep IT Partner Certifications And Training

PHILADELPHIA, April 21, 2021 (GLOBE NEWSWIRE) — Anexinet Corporation, a leading provider of digital business solutions, today announced that CRN, a brand of The Channel Company, has recognized Anexinet on its 2021 Tech Elite 250 list. Anexinet rose to the top of the solution-provider pack for maintaining the highest levels of certification and training from their partners and for its excellence in digitally transforming client networks.

“CRN’s Tech Elite 250 list highlights the top solution providers in the IT channel with the most in-depth technical knowledge, expertise, and certifications for providing the best level of service for their customers,” said Blaine Raddon, CEO of The Channel Company. “These solution providers have continued to extend their talents and abilities across various technologies and IT practices, demonstrating their commitment to really conveying the most exceptional business value to their customers.”

As the COVID-19 pandemic and the resulting recession forced organizations to adjust the way they operate, many relied on solution providers to survive, by rapidly adapting to the “new normal.” Anexinet helps companies across all industry verticals overcome operational roadblocks, improve customer experiences, and future-proof their digital networks against unforeseen challenges, through automation, backup & archiving, disaster recovery, cloud & hybrid IT, cybersecurity, managed services, and much more.

“Having achieved high levels of certification from the industry’s top IT providers, Anexinet brings a truly vendor-agnostic approach to architecting best-fit digital transformation strategies and solutions for our customers,” said John Kolimago, EVP, Anexinet. “We are humbled that our partner qualifications have been consistently recognized by CRN for delivering deep expertise and best-of-breed innovations.”

Follow Anexinet on TwitterLinkedIn, Facebook, or via the Anexinet Insights Blog.

About Anexinet

From intelligent, full-stack engagement strategies and solutions to modern, secure infrastructure products and services, Anexinet focuses on technology-enabled business transformation that drives value. For over two decades, Anexinet has helped companies worldwide solve their most complex challenges—from engaging front-end interactions to dependable back-end solutions. Anexinet’s record of client success springs from a culture rooted in thought leadership and delivery excellence. For more information, please visit www.anexinet.com or follow Anexinet on Twitter or LinkedIn.

For more information, contact:
Betsey Rogers
Public Relations
BridgeView Marketing
603-821-0809
[email protected]



JinkoSolar Wins “Asia’s Best Employer” Award for Third Consecutive Year by Optimizing Talent Development

PR Newswire

SHANGRAO, China, April 21, 2021 /PRNewswire/ — JinkoSolar Holding Co., Ltd (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it has won the award for “Asia’s Best Employer” for the third consecutive year. The Company’s diversified talent training and development programs aims to promote a corporate culture that fosters innovation and leadership among teams.

Organized by HR Asia, an authoritative human resources magazine, the award for “Asia’s Best Corporate Employer” recognizes enterprises with outstanding performance in human resource policies, and is one of Asia’s most authoritative awards in the field of human resource management. Every company shortlisted for the award goes through an independent review panel composed of senior professionals, renowned scholars, journalists, and government representatives in Asia. To ensure the objectivity of the professional evaluation and analysis of the final results, evaluations were conducted based on the “Employee Appraisal Report” and “Enterprise and Employer Engagement Survey Report”.

JinkoSolar has continuously optimized its employment practices, in order to create a family-like working environment for all employees, and to cultivate and develop talent at different levels within the organization. JinkoSolar currently has a complete ecosystem of scientific, standardized and personnel management systems, and it has been recognized for promoting best practices and values in human resource management, enhancing corporate culture and fostering equality, accountability and integrity.

Mr. Xiande Li, Chairman of the Board of Directors and Chief Executive Officer commented: “Talent is the cornerstone of an enterprise’s strategy to stay competitive and continuously innovate and JinkoSolar places great importance on developing its talent pool. We cultivate excellent working conditions and provide continuous learning through employee development platforms for professional training and advancement. We are a people-oriented company and will continue to invest in the future of our people.”

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and other countries and regions. JinkoSolar has built a vertically integrated solar product value chain, with an integrated annual capacity of 22 GW for mono wafers, 11 GW for solar cells, and 31 GW for solar modules, as of December 31, 2020.

JinkoSolar has 9 productions facilities globally, 20 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, United States, Mexico, Brazil, Chile, Australia, Portugal, Canada, Malaysia, UAE, Kenya, Denmark, and global sales teams in China, United Kingdom, France, Spain, Bulgaria, Greece, Ukraine, Jordan, Saudi Arabia, Tunisia, Morocco, Kenya, South Africa, Costa Rica, Colombia, Panama, Kazakhstan, Malaysia, Myanmar, Sri Lanka, Thailand, Vietnam, Poland and Argentina, as of December 31, 2020.

To find out more, please see: www.jinkosolar.com

Safe-Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends, “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release and the Company’s operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Ms. Stella Wang
JinkoSolar Holding Co., Ltd.
Tel: +86 21-5180-8777 ext.7806
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/jinkosolar-wins-asias-best-employer-award-for-third-consecutive-year-by-optimizing-talent-development-301273737.html

SOURCE JinkoSolar Holding Co., Ltd.